sparsentan

AssetAlso RE-021, PS-433540, Filspari

Blocks endothelin A and angiotensin II type 1 receptors to reduce proteinuria and protect kidney function.

Stage: Phase 3
Modality: Small molecule
Target: AGTR1; 1
Indication: 1
Trial: 1
Developer

Indications

1

Immunoglobulin a nephropathy
Phase 3, Completed, NCT03762850, clinicaltrials.gov, 17 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Trials1
Evidence for its targets3
Competitors11
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.